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CC BY-NC-ND license (http://creativeBackground/purpose: The pneumonia severity index (PSI) both contains some risk factors of
drug-resistant pathogens (DRPs) and represents the severity of health care-associated pneu-
monia. The aim of this study was to investigate whether the PSI could be used to predict DRPs
and whether there were risk factors beyond the PSI.
Methods: A retrospective observational study enrolled 530 patients with health care-
associated pneumonia who were admitted from January 2005 to December 2010 in a tertiary
care hospital.
Results: A total of 206 patients (38.9%) had DRPs, of which the most common was Pseudomonas
aeruginosa (24.3%). The incidence of DRPs increased with increasing PSI classes (6.7%, 25.5%,
36.9%, and 44.6% in PSI II, III, IV, and V, respectively). An analysis of the risk factors for DRPs by
PSI classes revealed that wound care was associated with methicillin-resistant Staphylococcus
aureus (MRSA) infection in PSI V (p Z 0.045). Nasogastric tube feeding (odds ratio, 3.88; 95%
confidence interval, 1.75e8.60; p Z 0.006), and bronchiectasis (odds ratio, 3.12; 95% confi-
dence interval, 0.66e14.69; p Z 0.007) were risk factors for DRPs in PSI III and IV. The area
under the receiver operating characteristic curve progressed from 0.578 to 0.651 while inte-
grating these risk factors with PSI classes.
Conclusion: The findings suggested that PSI plus risk factors predicted the risk of DRPs. PSI II
had a low risk of DRPs and could be treated as community-acquired pneumonia. Antibioticshave no conflicts of interest relevant to this article.
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Pneumonia severity index with risk factors 357of PSI III and IV with risk factors could be targeted DRPs. PSI V with wound care had a higher risk
of MRSA, and empirical anti-MRSA antibiotics could be added.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Obtaining microbiological information as quickly as possible
remains a challenge when treating patients with pneu-
monia. Pneumonia is classified as community-acquired
pneumonia (CAP) and hospital-acquired pneumonia (HAP),
which suggests the possible pathogens and therefore the
choice of antibiotics in the early phase of the treatment for
pneumonia.1,2 However, several studies have reported that
some CAP patients are at a greater risk of gram-negative
bacteria and pathogens resistant to conventional CAP
antibiotics.3e5 The 2005 American Thoracic Society/Infec-
tious Disease Society of America (ATS/IDSA) guidelines first
defined the subgroup of CAP as health care-associated
pneumonia (HCAP), and recommended broad-spectrum
antibiotics similar to those used for HAP.6 However, some
studies do not suggest the use of empirical broad-spectrum
antibiotics because HCAP is actually a heterogeneous
group.7 Predicting the occurrence of drug-resistant patho-
gens (DRPs) at diagnosis is one of the most important issues
in patients with HCAP, thereby avoiding inadequate or
overuse of broad-spectrum antibiotics. Several risk factors
for DRPs in HCAP, including hospitalization in the past 90
days, recent antibiotic therapy in the past 6 months, poor
functional status, and immune suppression, have been
reported.7e10
According to the 2005 ATS/IDSA guidelines for HAP,
ventilator-associated pneumonia, and HCAP, the selection
of empirical antibiotics should take into consideration the
risk factors for DRPs, but not include the severity of the
patient’s disease.6 However, according to studies of CAP,
stratification of the severity of disease can guide decisions
on the site of care and also the selection of antibiotics.11,12
Therefore, we hypothesized that the severity of HCAP
would be correlated with DRPs. However, there are
currently no well-accepted methods to evaluate the
severity of HCAP. Some investigators have shown that pre-
dictive scoring systems, such as the pneumonia severity
index (PSI) or CURB-65, can also be used with HCAP.13,14
Because risk factors suggestive of DRPs10,15 overlap with
some items of the PSI, we planned to use the PSI to eval-
uate the severity of HCAP. We conducted this retrospective
observational study at a tertiary care hospital. The primary
end-point was the correlation between PSI and DRPs. The
secondary end-point was to identify whether there were
additional risk factors for DRPs beyond the PSI.
Materials and methods
Patients who were admitted to our 800-bed tertiary care
hospital in Taiwan, from January 2005 to December 2010,
were screened by discharge diagnosis. The medical recordsof the patients whose primary discharge diagnosis was
pneumonia (International Classification of Diseases codes
482, 485, and 486) were reviewed. The patients were
enrolled if they fulfilled the criteria for HCAP,6 which were
defined as follows: patients who had been hospitalized in
an acute care hospital for  2 days within the past 90 days;
residents of a nursing home or long-term care facility; re-
cipients of recent intravenous antibiotic therapy, chemo-
therapy or wound care within the past 30 days; or patients
who attended a hospital or hemodialysis clinic. Because of
the uncertain clinical course, the patients who had been
transferred from other hospitals after hospitalization were
excluded. The Institutional Review Board of the Far Eastern
Memorial Hospital, New Taipei City, Taiwan approved this
study (IRB 102013-E).
The definition of steroid use was a daily steroid dose of
> 10 mg lasting for > 3 months. Chronic kidney disease was
defined as an estimated glomerular filtration rate < 30 mL/
min without the need for hemodialysis. Chemotherapy was
defined as having undergone chemotherapy within 60 days
for a malignancy. Although arterial blood gas data were not
available in some patients, arterial partial pressure of ox-
ygen was considered to be < 60 mmHg if oxygen saturation
measured by pulse oximetry was < 90% in room air. The
data on causative pathogens were obtained from sputum
cultures and/or the cultures of sterile specimens within 24
hours after the diagnosis of pneumonia had been estab-
lished, e.g., from blood or pleural effusion. The data of
sputum culture were reported in a semiquantitative
manner. Possible causative pathogens were identified from
sputum if the collected sputum samples were of sufficient
quality, defined as > 25 polymorphonuclear cells and < 10
epithelial cells per power field with a total
magnification  100, and a moderate or heavy amount of
growth in the cultures. DRPs were defined as those not
sensitive to the antibiotics suggested for CAP treatment,
such as b-lactam, macrolide, and respiratory fluo-
roquinolones.12 The initial antibiotic treatment was classi-
fied as being inappropriate if the initially prescribed
antibiotics were not active against the identified pathogens
based on in vitro susceptibility testing.15 Antibiotics against
Pseudomonas aeruginosa and methicillin-resistant Staphy-
lococcus aureus (MRSA) were defined as the broad-
spectrum antibiotics. PSI scores and grouping were calcu-
lated according to the principles of the Pneumonia Patient
Outcomes Research Team cohort study on CAP.16 PSI is
based on age and the presence of coexisting disease
including neoplastic disease, liver disease, renal disease,
cerebrovascular disease, and congestive heart failure,
abnormal physical findings (such as respiratory rate, body
temperature, pulse, blood pressure), and mental status as
well as abnormal laboratory and radiographic findings
(blood pH, urea nitrogen concentration, blood sugar,
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pressure, or pleural effusion) at presentation. Severity was
classified into four groups as follows: PSI class II ( 70), III
(71e90), IV (91e130), and V (> 130).
All data were expressed as mean  standard deviation
unless otherwise stated. Statistical analysis was performed
using SPSS version 18 software (SPSS Inc., Chicago, IL, USA).
Continuous data were compared using Student t test, and
categorical data including demographics, outcomes, anti-
biotics, and microbiology were compared using Man-
neWhitney U test. Odds ratios (ORs) and their 95%
confidence intervals (CIs) were calculated. The relationship
between the PSI and DRPs was calculated using analysis of
variance. The validity of the PSI and the predictive ability
were evaluated using receiver operating characteristic
(ROC) curves. A p value < 0.05 was considered to indicate
statistical significance.
Results
Patient demographics
During the study period, 1633 patients were admitted with
a primary discharge diagnosis of pneumonia, of whom 530
(32.5%) met the criteria of HCAP. The demographic and
morbidity data are shown in Table 1. The most common
criterion of HCAP was past admission within 90 days, fol-
lowed by recipients of antibiotics within 90 days and
residing in a nursing home. The most prevalent morbidity
was cerebrovascular illness.Table 1 Demographic and morbidity characteristics.
Total (N Z 530) PSI II (N Z 15)
Age (y) 75.1  12.8 49.7  14.5*
Sex (M/F) 349/181 10/5
ICU 116 (21.9) 1 (6.7)
Admission within 90 d 317 (59.8) 5 (33.3)
Nursing home 224 (42.3) 2 (13.3)*
Antibiotics within 30 d 123 (23.2) 4 (26.7)
Antibiotics within 90 d 232 (43.8) 4 (26.7)
Active chemotherapy 47 (8.9) 3 (20)
Steroid use 63 (11.9) 4 (26.7)*
Wound care 103 (19.4) 1 (6.7)
Hemodialysis 48 (9.1) 4 (26.7)*
CVA, n (%) 264 (49.8) 0
Malignancy 140 (26.4) 3 (20)
DM 220 (41.5) 5 (33.3)
CKD 89 (16.8) 2 (13.3)
Heart failure 84 (15.8) 2 (13.3)
COPD 191 (36) 2 (13.3)
Bronchiectasis 27 (5.1) 1 (6.7)
Liver cirrhosis 20 (3.8) 0
Data are presented as n (%) or mean  SD, unless otherwise indicate
*p < 0.001 PSI II versus PSI III, IV, and V.
**p < 0.001 PSI II, III versus PSI IV and V.
CKDZ chronic renal disease; COPDZ chronic obstructive pulmonary d
ICU Z the care of intensive care unit during the first 3 days of admisWhen stratified by PSI score, the PSI class II patients
were significantly younger than the other patients (49.7
þ/ 14.5 v.s. 75.8 þ/ 12.0 p < 0.001). Chronic steroid use
and hemodialysis were more prevalent in PSI class II pa-
tients than in PSI class IV and V patients (p < 0.001).
However, more patients with PSI class IV and V resided in
nursing homes compared to patients with PSI class II and III
(p < 0.001). The most significant difference in comorbid-
ities between PSI classes was cerebrovascular illnesses
(p < 0.001). This represented that patients with PSI class IV
and V were in poor functional status.Microbiology
As shown in Table 2, only 35 (6.6%) patients had positive
blood culture results. There was no significant difference in
the prevalence of positive blood culture results between
the patients with PSI class IIIeV. The leading pathogen was
Klebsiella pneumoniae followed by Escherichia coli. The
incidence of MRSA was 8.5% in patients with bacteremia.
The causative agents are shown in Table 3. Causative
microorganisms were identified in 286 (48%) patients.
Among these patients, 35 (12.2%) were identified by blood
culture, 73 (25.5%) by endobronchial tube aspiration, and
the other 178 (62.7%) by sputum culture. The three most
common pathogens were P. aeruginosa (24.3%), K. pneu-
moniae (8.3%), and Haemophilus influenzae (7.9%). A total
of 206patients (38.9%) had DRPs. The leading pathogens of
DRPs were P. aeruginosa, MRSA, Stenotrophomonas malto-
philia, and Acinetobacter baumannii.PSI III (N Z 51) PSI IV (N Z 195) PSI V (N Z 269)
66.4  11.7 73.3  12.5 79.5  10.2
31/20 139/56 169/100
3 (5.9) 15 (7.7) 97 (36.1)
30 (58.8) 124 (63.6) 158 (58.7)
8 (15.7) 82 (42.1) 132 (49.1)
14 (27.5) 38 (19.2) 67 (24.9)
19 (37.3) 84 (43.1) 125 (46.5)
4 (7.8) 21 (10.8) 19 (7.1)
9 (17.6) 37 (19) 13 (4.8)
7 (13.7) 40 (20.5) 55 (20.4)
11 (21.6) 14 (7.2) 19 (7.1)
1 (2) 95 (48.7) 168 (62.5)**
8 (15.7) 45 (23.1) 85 (31.6)
17 (33.3) 70 (35.9) 128 (47.6)
9 (17.6) 25 (12.8) 54 (20.1)
4 (7.8) 26 (13.3) 52 (19.3)
17 (33.3) 74 (37.9) 98 (36.1)
6 (11.7) 10 (5.1) 10 (3.7)
0 5 (2.6) 15 (5.6)
d.
isease; CVAZ cerebrovascular illnesses; DMZ diabetes mellitus;
sion; PSI Z pneumonia severity index.
Table 2 Pathogens identified by blood culture.
Total (N Z 530) PSI II (N Z 15) PSI III (N Z 51) PSI IV (N Z 195) PSI V (N Z 269)
Blood culture 35 (6.6) 0 (0) 4 (7.8) 10 (5.1) 21 (7.8)
Gram positive
Streptococcus pneumoniae 4 (0.8) 0 (0) 1 (2.0) 0 (0) 3 (1.1)
MSSA 2 (0.4) 0 (0) 0 (0) 0 (0) 2 (0.7)
MRSA 3 (0.6) 0 (0) 0 (0) 0 (0) 3 (1.1)
b-Streptococcus 3 (0.6) 0 (0) 0 (0) 1 (0.5) 2 (0.7)
Gram negative
Klebsiella pneumoniae 8 (1.5) 0 (0) 2 (3.9) 1 (0.5) 5 (1.9)
Escherichia coli 6 (1.1) 0 (0) 1 (2.0) 0 (0) 5 (1.9)
Haemophilus influenzae 2 (0.4) 0 (0) 0 (0) 1 (0.5) 1 (0.4)
Proteus mirabilis 1 (0.2) 0 (0) 0 (0) 1 (0.5) 0 (0)
Pseudomonas aeruginosa 2 (0.4) 0 (0) 0 (0) 2 (1.0) 0 (0)
Acinetobacter baumanni 3 (0.6) 0 (0) 0 (0) 3 (1.5) 0 (0)
Chryseobacterium 1 (0.2) 0 (0) 0 (0) 1 (0.5) 0 (0)
Data are presented as n (%).
MSSA Z methicillin-sensitive S. aureus; MRSA Z methicillin-resistant S. aureus; PSI Z pneumonia severity index.
Table 3 Causative organisms of health care-associated pneumonia.
Total (N Z 530) PSI II (N Z 15) PSI III (N Z 51) PSI IV (N Z 195) PSI V (N Z 269)
Pathogens sensitive to CAP antibiotics regimen
Streptococcus pneumonia 16 (3.0) 0 4 (7.8) 7 (3.6) 5 (1.9)
MSSA 13 (2.5) 0 0 4 (2.1) 9 (3.3)
b-Streptococcus 15 (2.8) 0 1 (2.0) 5 (2.6) 9 (3.3)
Klebsiella pneumoniae 42 (7.9) 1 (6.7) 2 (3.9) 15 (7.7) 24 (8.9)
Escherichia coli 18 (3.4) 0 0 7 (3.6) 13 (4.8)
Haemophilus influenzae 42 (7.9) 0 4 (7.8) 17 (8.7) 21 (7.8)
Moraxella catarrhalis 1 (0.2) 0 0 (0) 1 (0.5) 2 (0.7)
Morganella morganii 5 (0.9) 0 0 (0) 3 (1.5) 2 (0.7)
Proteus mirabilis 23 (4.3) 0 4 (7.8) 6 (3.1) 13 (4.8)
Enterobacter cloacae 16 (3.0) 0 4 (7.8) 4 (2.1) 8 (3.0)
Serratia marcescens 33 (6.2) 0 1 (2.0) 13 (6.7) 19 (7.1)
Pathogens resistant to CAP antibiotics regimen
MRSA 37 (7.0) 0 3 (5.9) 9 (4.6) 25 (9.3)
Klebsiella pneumoniae 2 (0.4) 0 (0) 0 (0) 1 (0.5) 1 (0.4)
Escherichia coli 8 (1.5) 0 (0) 0 (0) 5 (2.6) 3 (1.1)
Proteus mirabilis 2 (0.4) 0 (0) 0 (0) 1 (0.5) 1 (0.4)
Pseudomonas aeruginosa 129 (24.3) 1 (6.7) 9 (17.6) 46 (23.6) 73 (27.1)
Acinetobacter baumannii 25 (3.7) 0 1 (2.0) 7 (3.6) 17 (6.3)
Stenotrophomonas maltophilia 22 (4.2) 0 1 (2.0) 6 (3.1) 15 (5.6)
Chryseobacterium 1 (0.2) 0 (0) 0 (0) 1 (0.5) 0 (0)
Data are presented as n (%).
CAP Z community-acquired pneumonia; MSSA Z methicillin-sensitive S. aureus; MRSA Z methicillin-resistant S. aureus.
Pneumonia severity index with risk factors 359Incidence of DRPs and in-hospital mortality in the
PSI groups
The incidence of DRPs (6.6%, 25.5%, 36.9%, and 44.6% in PSI
II, III, IV, and V, respectively) and in-hospital mortality rate
(0%, 5.9%, 12.3%, and 23.8%, respectively) increased with
increasing PSI classes (Fig. 1). The area under ROC curve of
the PSI was 0.578 (95% CI, 0.529e0.627) to predict DRPs and
0.632 (95% CI, 0.574e0.690) to predict the in-hospital
mortality.Risk factors of DRPs beyond PSI
The rate of inappropriate antibiotic treatment was not
significantly different among the various PSI groups. How-
ever higher in-hospital mortality rates were noted in pa-
tients who received inappropriate antibiotic treatment in
the PSI III and IV groups (20% and 22.6%, respectively)
compared to those with appropriate antibiotic treatment
[2.4% (PSI III) and 10.4% (PSI IV), p Z 0.036 and pZ 0.058,
respectively], as shown in Fig. 2. However, the in-hospital
mortality rates in the PSI V group were similar regardless
Figure 1 Incidences of multiple-drug resistant pathogens, broad-spectrum antibiotics, in-hospital mortality, and inappropriate
antibiotic use among PSI classes. The incidences of drug resistant pathogens, broad-spectrum antibiotic use, and in-hospital mortality
rate increased with increasing PSI score. The rate of inappropriate antibiotic use was not significantly different among the PSI IIIeV
classes. DRPsZ pathogens resistant to the treatment regimen of community acquired; PSIZ pneumonia severity index.
Figure 2 Incidences of inappropriate antibiotic use and in-hospital mortality among the PSI IIIeV classes. Higher in-hospital
mortality rates of the patients receiving inappropriate antibiotic therapy compared with those with appropriate antibiotic ther-
apy in the PSI III (*p Z 0.036) and IV (**p Z 0.058) classes. PSI Z pneumonia severity index.
360 P.-H. Wang et al.of whether or not the patients received inappropriate
antibiotic treatment. Therefore, identification of risk fac-
tors beyond the PSI is mandatory to better predict the DRPs
in patients with PSI III and IV.
Multivariate analysis was performed on the PSI III and IV
classes. Nasogastric tube feeding (OR, 3.88; 95% CI,
1.75e8.60; pZ 0.006) and bronchiectasis (OR, 3.12; 95% CI,
0.66e14.69; pZ 0.007) were risk factors for DRPs in patients
withPSI III and IV. TheareaunderROCof these two risk factors
in patientswith PSI III and IVwas 0.651 (95%CI, 0.577e0.725).
The risk factors for MRSA were analyzed in the PSI
classes, and the only significant difference was noted in the
PSI V class, in which wound care was significantlyassociated with MRSA infection (OR, 3.57; 95% CI,
1.52e8.39; p Z 0.002).Algorithm of antibiotics selection by integrating PSI
and risk factors
From the results of the current study, we suggest an algorithm
for the selectionofantibiotics forpatientswithHCAPas shown
in Fig. 3. Antibiotic regimens for CAP may then be considered
for patients with PSI II because of the low risk of DRPs. Broad-
spectrum antibiotics covering P. aeruginosa are suggested for
those with PSI III and IV with bronchiectasis and tube feeding.
Antibiotics forMRSA shouldbeconsidered inPSI Vpatientswho
Figure 3 Proposed algorithm of health care-associated pneumonia therapy. Health care-associated pneumonia severity is first
evaluated by PSI. Antibiotic regimens for community acquired pneumonia may then be considered for patients with PSI II owing to
the low risk of drug-resistant pathogens. Board-spectrum antibiotics covering Pseudomonas aeruginosa are suggested for those with
PSI III and IV with bronchiectasis or tube feeding. Antibiotics covering MRSA should be taken into consideration for PSI V patients
who received wound care within 1 month, in addition to broad-spectrum antibiotics covering P. aeruginosa. CAP Z community
acquired pneumonia; DRPs Z pathogens resistant to the treatment regimen of community-acquired pneumonia;
MRSA Z methicillin-resistant Staphylococcus aureus; NG Z nasogastric tube feeding; PSI Z pneumonia severity index.
Pneumonia severity index with risk factors 361received wound care within 1 month, in addition to broad-
spectrum antibiotics covering P. aeruginosa.Discussion
The results of this study showed that the PSI could predict
both mortality and the risk of DRPs in patients with HCAP.
However, there was a better performance when integrating
the PSI with the risk factors for DRPs than PSI alone.
Previous studies suggested the key role of MRSA and P.
aeruginosa in the pathogenesis of HCAP.15,17,18 Hence, in
2005 the ATS/IDSA guidelines recommended anti-
Pseudomonas plus anti-MRSA antibiotics as the empirical
therapy for HCAP.6 The current study also showed that P.
aeruginosa was the leading pathogen in HCAP, and that
MRSA had less of an impact on HCAP patients than in other
studies. A similar result was reported in Taiwan by Wu
et al,19 who noted that the incidence of MRSA was only 7.8%
in patients with HCAP. The widespread use of empirical
anti-MRSA therapy for HCAP may not be cost-effective in
Taiwan, and the current study showed that the risk of MRSA
infection increased in patients with PSI class V and the
comorbidity of wound care.
To our knowledge, there is no well-established severity
scoring system for HCAP. Scoring systems for CAP severity
such as the PSI, CURB-65, or severe community-acquired
pneumonia have also been evaluated in the performance of
predicting HCAP outcomes.13,14,20,21 There were some de-
bates about the performance of these scoring systems. Fal-
cone and his colleagues21 proposed that these scoring
systems were less useful in patients with HCAP than in thosewith CAP. However, some investigators suggested that PSI
had a better performance than CURB-65 in HCAP, which may
be more related to the demographic characteristics and
comorbidities of HCAP thanCURB-65.14,20 Our results showed
the similar prediction power of PSI to those of previous
studies.14,16,20 Although the prediction power of PSI in HCAP
was not as good as in CAP, PSI might be used as a severity
scoring system of HCAP before a better one is developed.
Several risk factors of DRPs, but not pneumonia severity,
have been reported in several studies.9,10,15 However, some
studies reported that a critical illness requiring intensive
care or mechanical ventilation was a risk factor for
DRPs.7,22,23 Nevertheless, Shindo et al24 reported that HCAP
severity evaluated by the A-DROP scoring system (age,
dehydration, respiratory failure, oriented consciousness,
and low blood pressure) was not related to the incidence of
DRPs. Conversely, our results demonstrated that the PSI in
HCAP patients could predict the risk of DRPs. The advan-
tages of the PSI over the A-DROP system were that some of
the risk factors for resistant bacteria were included in its
items, and that it also represents illness severity.
The current study reported that bronchiectasis and
enteric tube feeding were additional risk factors beyond PSI
in PSI III and IV patients. The integration of these two risk
factors and PSI in PSI III and IV patients improved the pre-
dictive power of PSI for DRPs, which is comparable with the
prediction power of Shorr et al’s22 and Aliberti et al’s8
scoring systems. The advantage of our model is that not
only can it predict the risk of DRPs, but it can also predict
in-hospital mortality.
Ewig and colleagues25 proposed a new insight of HCAP,
focusing on the importance of functional status and daily
362 P.-H. Wang et al.living activity levels in pneumonia treatment and classifi-
cations. Our results also support this viewpoint. One risk
factor of DRPs in PSI III and IV, enteric tube feeding, implied
poor functional status. Thereafter, functional status might
play a more important role beyond the concept of HCAP and
CAP treatment.
In the absence of culture data, early and appropriate
empiric antimicrobial treatment is important to optimize
outcomes.26 This was also found in the current study,
except for patients with PSI V. The most likely reason for
this is that most patients with PSI V died owing to under-
lying patient-related factors and severe illnesses rather
than the presence of antibiotic-resistant pathogens.27
Another possible reason is the nonaggressive or limited
treatment for HCAP. The lower use of advanced and
intensive care including intensive care unit admission,
mechanical ventilation, and the need for vasopressors have
been reported for patients with severe HCAP.28
The patients with PSI II seemed to be a unique group.
They were younger and had a better functional status, but
a higher use of immunosuppressants and hemodialysis. They
also had less microbiological evidence compared with other
patients. The patients with negative culture results possibly
had a lower severity of illness compared with those who
had positive culture results.29 This suggests that conven-
tional therapy against CAP may be adequate for PSI II pa-
tients and may not lead to an increase in mortality rate.
A limitation to this study is that the microbiology data
mainly came from sputum cultures, and there was little
information about atypical pathogens such as Legionella,
Mycoplasma, and virus. Interpretation of sputum cultures is
confounded by the high rate of oropharyngeal colonization
by aerobic gram-negative bacilli and S. aureus.30 However,
invasive procedures are not always indicated and feasible
for HCAP patients, and aspiration of oropharyngeal secre-
tions is usually considered a major risk factor for pneu-
monia in the institutionalized elderly. Therefore,
microorganisms in sputum cultures may represent the
causative pathogens. Another limitation of this study is that
data on blood pH were only available for 362 individuals
while calculating the PSI. If no data were available, a pH
value of > 7.35 was assumed. However, this assumption
may have had some impact on the PSI scores.
In conclusion, the PSI is useful not only in CAP, but also in
HCAP, to evaluate the risks of mortality and resistant
pathogens. If patients are stratified by PSI score and
weighted by extra risk factors, more appropriate broad-
spectrum antibiotics may be prescribed, thereby avoiding
unnecessary antibiotic treatment and bacterial resistance.References
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